SOURCE: Atossa Genetics Inc

Atossa Genetics Inc

September 04, 2014 08:00 ET

Atossa Genetics to Present at Two Upcoming Investor Conferences

SEATTLE, WA--(Marketwired - Sep 4, 2014) - Atossa Genetics Inc. (NASDAQ: ATOS) today announced that it will be a featured presenter at the Rodman & Renshaw 16th Annual Global Investment Conference, on September 10, 2014 at the New York Palace Hotel in New York City. Management will present the company's business model and growth strategy at 2:05pm EDT in the Kennedy II Salon (4th Floor). Atossa Genetics will also be a featured presenter at the 2014 Aegis Healthcare & Technology Conference on September 11, 2014 from 08:00 to 08:25 AM in Chopin 1, at The Encore at Wynn Las Vegas. Management will be available for one-on-one meetings throughout the conferences.

The Rodman & Renshaw 16th Annual Global Investment Conference will be held September 9 and 10, 2014 at the New York Palace Hotel in New York City. For more information or to register for the conference, please visit the conference website at http://www.rodm.com.

The 2014 Aegis Healthcare & Technology Conference will be held September 11 - 13, 2014 at The Encore at Wynn Las Vegas. For more information or to register for the conference please visit: http://www.aegiscapcorp.com/

About Atossa Genetics

Atossa Genetics Inc. is focused on improving breast health through the development of laboratory services, medical devices and therapeutics. The laboratory services are being developed by the Company's subsidiary, The National Reference Laboratory for Breast Health, Inc. The laboratory services and the Company's medical devices are being developed so they can be used as companions to therapeutics to treat various breast health conditions. For additional information, please visit www.atossagenetics.com.

Forward-Looking Statements

Forward-looking statements in this press release are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with actions by the FDA, including timing of review by the FDA of 510(k) submissions, and actions related thereto including whether the FDA agrees with study design, protocol and conclusions, whether Atossa can submit additional information to the FDA in a timely fashion and whether the FDA will find that information acceptable and/or request additional information, the outcome of the FDA re-inspection completed on March 14, 2014, the outcome or timing of regulatory clearances needed by Atossa to sell its products, responses to regulatory matters, Atossa's ability to continue to manufacture and sell its products, recalls of products, the efficacy of Atossa's products and services, performance of distributors, estimated future expenses and cash needs, whether Atossa can launch in the United States and foreign markets the additional tests, devices and therapeutics in its pipeline in a timely and cost effective manner, and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.